Efficacy and Safety of Intra-Articular Platelet-Rich Plasma in Osteoarthritis Knee: A Systematic Review and Meta-Analysis
Autor: | Qidong Zhang, Yan Yan, Wanshou Guo, Xiaowei Sun, Chongjie Cheng, Mao Hong, Weiguo Wang |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2021 |
Předmět: |
medicine.medical_specialty
WOMAC Visual Analog Scale Article Subject Visual analogue scale Osteoarthritis Cochrane Library Placebo General Biochemistry Genetics and Molecular Biology Injections Intra-Articular law.invention 03 medical and health sciences 0302 clinical medicine Randomized controlled trial law Internal medicine medicine Humans Hyaluronic Acid Adverse effect Aged 030203 arthritis & rheumatology General Immunology and Microbiology Platelet-Rich Plasma business.industry Anti-Inflammatory Agents Non-Steroidal Chondroitin Sulfates 030229 sport sciences General Medicine Middle Aged Osteoarthritis Knee medicine.disease Treatment Outcome Platelet-rich plasma Medicine business Research Article |
Zdroj: | BioMed Research International, Vol 2021 (2021) BioMed Research International |
ISSN: | 2314-6133 |
DOI: | 10.1155/2021/2191926 |
Popis: | Background. Knee osteoarthritis (KOA) is a common disease in aged adults. Intra-articular (IA) injection of platelet-rich plasma (PRP) therapy is an effective minimally invasive treatment for KOA. We aimed to compare the efficacy and safety of platelet-rich plasma (PRP) with placebo or other conservative treatments. Methods. We conducted a meta-analysis to identify relevant articles from online register databases such as PubMed, Medline, Embase, and the Cochrane Library. The primary outcomes were the visual analogue scale (VAS) score, Western Ontario and McMaster Universities Arthritis Index (WOMAC) score, and International Knee Documentation Committee (IKDC) subjective score. The secondary outcome was the adverse event rate. Results. A total of 895 articles were identified, of which 23 randomized controlled trials that met the inclusion criteria were determined as eligible. Compared with placebo, PRP had a lower VAS score and higher IKDC subjective score at the 6th month after treatment and significantly less WOMAC score during the follow-up period. Compared with oral NSAIDs, PRP gained a lower WOMAC score at the 6th month after treatment. The VAS score decreased after treatment when reaching PRP and CS. As compared to the HA, the VAS score, WOMAC score, and IKDC subjective score all revealed better PRP results. There were no significant differences in adverse event rates comparing PRP versus placebo or HA. Different PRP applications did not show significant differences in VAS score in the 1st month and WOMAC score in the 3rd month after treatment. Conclusion. To compare with the conservative treatments mentioned above, PRP is more effective in relieving symptoms. There were no significant differences between triple PRP application and single PRP application in short-term curative effect. |
Databáze: | OpenAIRE |
Externí odkaz: | |
Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |